Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Davis

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2008
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysGeorg Lenz, George W Wright, N C Tolga Emre, et al.
Cancer Cell|May 7, 2019
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell LethalityJo Ishizawa, Sarah F Zarabi, R Eric Davis, et al.
Science Translational Medicine|June 21, 2019
Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphomaNeeraj Jain, Keenan Hartert, Saber Tadros, et al.
Cancer Cell|May 3, 2016
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 SignalingXing-Ding Zhang, Veerabhadran Baladandayuthapani, Heather Lin, et al.
Haematologica|April 1, 2021
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMan Chun John Ma, Saber Tadros, Alyssa Bouska, et al.
Cancer Cell|December 16, 2010
Cooperative epigenetic modulation by cancer amplicon genesLixin Rui, N C Tolga Emre, Michael J Kruhlak, et al.
Cell Metabolism|April 10, 2018
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell TherapyTina Cascone, Jodi A McKenzie, Rina M Mbofung, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Nature|January 8, 2010
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaR Eric Davis, Vu N Ngo, Georg Lenz, et al.
Signal Transduction and Targeted Therapy|April 2, 2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2008
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysGeorg Lenz, George W Wright, N C Tolga Emre, et al.
Cancer Cell|May 7, 2019
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell LethalityJo Ishizawa, Sarah F Zarabi, R Eric Davis, et al.
Science Translational Medicine|June 21, 2019
Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphomaNeeraj Jain, Keenan Hartert, Saber Tadros, et al.
Cancer Cell|May 3, 2016
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 SignalingXing-Ding Zhang, Veerabhadran Baladandayuthapani, Heather Lin, et al.
Haematologica|April 1, 2021
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMan Chun John Ma, Saber Tadros, Alyssa Bouska, et al.
Cancer Cell|December 16, 2010
Cooperative epigenetic modulation by cancer amplicon genesLixin Rui, N C Tolga Emre, Michael J Kruhlak, et al.
Cell Metabolism|April 10, 2018
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell TherapyTina Cascone, Jodi A McKenzie, Rina M Mbofung, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Nature|January 8, 2010
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaR Eric Davis, Vu N Ngo, Georg Lenz, et al.
Signal Transduction and Targeted Therapy|April 2, 2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Pageof 17